Efficacy and Safety of Switching to Dolutegravir With Boosted Darunavir in Virologically Suppressed Adults With HIV-1: A Randomized, Open-Label, Multicenter, Phase 3, Noninferiority Trial: The DUALIS Study.

Christoph D SpinnerTim KümmerleJochen SchneiderChristiane CordesHans HeikenHans-Jürgen StellbrinkIvanka KrznaricStephan ScholtenBjörn JensenChristoph WyenMarin ViehwegerClara LehmannMartin SprinzlAlbrecht StoehrMarkus BickelHeiko JessenWilfried ObstPetra Spornraft-RagallerPavel KhaykinEva WolfChristoph Boeseckenull null

Published in: Open forum infectious diseases (2020)

Switching to DTG + bDRV was noninferior to continuing 3DR in subjects already treated with bDRV.

Keyphrases

hiv infected patients
antiretroviral therapy
hiv infected
open label
phase iii
clinical trial
phase ii
hiv positive
human immunodeficiency virus
study protocol
hiv aids
hepatitis c virus
hiv testing
cross sectional
double blind
newly diagnosed